Hologic Announces Fourth Quarter and Fiscal 2009 Operati...(estimated annual effective tax rate of 3...),Health

Non-GAAP Financial Guidance:

This press release also includes estimates of future non-GAAP adjusted earnings and earnings per share. A reconciliation of these amounts to expected GAAP results is presented below:

                                                                   Diluted
                           Three Months Ended                      Earnings
                            December 26, 2009       Shares         per Share
                            -----------------       ------         ---------

    (In thousands, except
     per share amounts)
    Projected GAAP Net
    Income                  $16,000 - $21,000      260,000     $0.06 - $0.08

    Adjustments:
      Cost of revenues -
       amortization of
       intangible assets               44,000 (1)
      Amortization of
       acquired intangible
       assets                          13,000 (1)
      Non-cash interest
       expense relating to
       recently-issued
       accounting guidance
       for convertible debt            17,000 (2)
      Income tax effect of
       reconciling items              (27,000)(3)
                                     --------

    Projected Non-GAAP
     Net Income             $63,000 - $68,000      260,000 (4) $0.24 - $0.26
                            =================      =======     =============



                                                                  Diluted
                          Twelve Months Ended                     Earnings
                           September 25, 2010       Shares        per Share
                           ------------------       ------        ---------

    (In thousands, except
     per share amounts)
    Projected GAAP Net
     Income               $110,000 - $120,000      260,000      $0.42 -$0.46

    Adjustments:
      Cost of revenues -
       amortization of
       intangible assets 
'/>"/>
SOURCE  Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients